6 completed, 1 terminated. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 6, Terminated 1 |
Follow benazepril: new trials by email Literature Review of benazepril trials Research Report on benazepril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia Placebo, Benazepril hydrochloride - Renal Alteration | Phase 3 | Completed | University Hospital, Geneva | 120 | 2010-04-01 | 2018-05-01 |
| Preventing ESRD in Overt Nephropathy of Type 2 Diabetes Benazepril, Valsartan, Benazepril/Valsartan - Diabetes | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 102 | 2007-05-01 | 2016-06-01 |
| Preventing Microalbuminuria in Type 2 Diabetes Benazepril, Valsartan, Benazepril/Valsartan - Diabetes | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 612 | 2007-05-01 | 2019-09-06 |
| Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension Benazepril plus hydrochlorothiazide - Hypertension | Phase 3 | Completed | Novartis | 296 | 2006-07-01 | 2007-07-09 |
| A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril. amlodipine/benazepril - Hypertension | Phase 3 | Completed | Novartis | 1422 | 2004-07-01 | 2016-04-06 |
| Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter - Hypertension | Phase 3 | Terminated | Novartis | 11506 | 2003-10-01 | 2023-10-24 |
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin - Atherosclerosis, Cardiovascular Diseases | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10251 | 1999-09-01 | 2016-11-22 |
Hypertension (4) · Diabetes Mellitus (3) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Diabetes Mellitus, Type 2 (1) · Heart Murmurs (1) · Hypercholesterolemia (1)
Novartis (3) · Mario Negri Institute for Pharmacological Research (2) · National Heart, Lung, and Blood Institute (NHLBI) (1) · University Hospital, Geneva (1)
United States (3) · Italy (2) · Canada (1) · China (1) · Denmark (1) · Finland (1) · Norway (1) · Slovenia (1) · Sweden (1) · Switzerland (1)
Denise Simons-Morton, MD, PhD (1) · Giuseppe Remuzzi, MD (1) · Piero Ruggenenti, MD (1) · Robert Byington, PhD (1) · William Friedewald, MD (1)
PMID 18539917, PMID 18776118, PMID 19052124, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20170948, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 20620720, PMID 21366473, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22723577, PMID 23033246, PMID 23219284, PMID 23238658, PMID 23412077, PMID 23990163, PMID 24170759, PMID 24296848, PMID 24493100, PMID 24595629, PMID 24779562, PMID 25088437, PMID 25127725, PMID 25159234, PMID 25172198, PMID 25193529, PMID 25229335, PMID 25267796, PMID 25652389, PMID 25666468, PMID 25887355, PMID 26261902, PMID 26459421
N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)